{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:08:12Z","timestamp":1790284092655,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s13555-024-01136-w","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T17:01:30Z","timestamp":1711213290000},"page":"933-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies"],"prefix":"10.1007","volume":"14","author":[{"given":"April","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Gonz\u00e1lez-Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Muzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Malatestinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lampropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Feely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Kyoungah","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Mert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"issue":"2","key":"1136_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et\u00a0al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1136_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3899\/jrheum.161473","volume":"44","author":"DD Gladman","year":"2017","unstructured":"Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, et\u00a0al. Treating psoriasis and psoriatic arthritis: position paper on applying the treat-to-target concept to Canadian daily practice. J Rheumatol. 2017;44(4):519\u201334.","journal-title":"J Rheumatol"},{"issue":"5","key":"1136_CR3","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et\u00a0al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1136_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, et\u00a0al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11(1):235\u201352.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1136_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40273-013-0126-6","volume":"32","author":"A Torbica","year":"2014","unstructured":"Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics. 2014;32(2):209\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1136_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","volume":"308","author":"C Blome","year":"2016","unstructured":"Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et\u00a0al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69\u201378.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1136_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1346-8138.14139","volume":"45","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264\u201372.","journal-title":"J Dermatol"},{"issue":"9993","key":"1136_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et\u00a0al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"1136_CR9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, et\u00a0al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014\u201323.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1136_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, et\u00a0al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70\u20139 (e3).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1136_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et\u00a0al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1136_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, et\u00a0al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1136_CR13","doi-asserted-by":"publisher","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","volume":"34","author":"A Reich","year":"2023","unstructured":"Reich A, Reed C, Schuster C, Robert C, Treuer T, Lubrano E. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016\u20132021. J Dermatolog Treat. 2023;34(1):2160196.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1136_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","volume":"40","author":"C Lynde","year":"2023","unstructured":"Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, et\u00a0al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869\u201386.","journal-title":"Adv Ther"},{"issue":"11","key":"1136_CR15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/jdv.18376","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Puig L, Sch\u00e4kel K, Reich A, Zaheri S, Costanzo A, et\u00a0al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087\u2013100.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1136_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/jdv.19161","volume":"37","author":"A Reich","year":"2023","unstructured":"Reich A, Pinter A, Maul JT, Vender RB, Torres T, Brnabic A, et\u00a0al. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. J Eur Acad Dermatol Venereol. 2023;37(9):1825\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1136_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/1793535","author":"LDP Mastorino","year":"2023","unstructured":"Mastorino LDP, Susca S, Cariti C, Siliquini N, Verrone A, Stroppiana E, Ortoncelli M, Quaglino P, Ribero S. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2023. https:\/\/doi.org\/10.1155\/2023\/1793535.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"1136_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10543406.2021.1998095","volume":"32","author":"A Zagar","year":"2022","unstructured":"Zagar A, Kadziola Z, Lipkovich I, Madigan D, Faries D. Evaluating bias control strategies in observational studies using frequentist model averaging. J Biopharm Stat. 2022;32(2):247\u201376.","journal-title":"J Biopharm Stat"},{"issue":"2","key":"1136_CR19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/09546634.2020.1782317","volume":"33","author":"M Radtke","year":"2022","unstructured":"Radtke M, Conrad C, Schuster C, Saure D, Mert C, Riedl E, et\u00a0al. Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response. J Dermatolog Treat. 2022;33(2):1168\u201370.","journal-title":"J Dermatolog Treat"},{"issue":"9993","key":"1136_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, Van De Kerkhof P, Paul C, Menter A, et\u00a0al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015;386(9993):541\u201351.","journal-title":"The Lancet"},{"issue":"9","key":"1136_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/jdv.16274","volume":"34","author":"JF Merola","year":"2020","unstructured":"Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, et\u00a0al. The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2020;34(9):2051\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1136_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.36849\/JDD.5821","volume":"20","author":"MJ Gooderham","year":"2021","unstructured":"Gooderham MJ, Elewski B, Augustin M, Iversen L, Torii H, Burge R, et\u00a0al. Effect of ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies. J Drugs Dermatol. 2021;20(4):394\u2013401.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1136_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244\u201352.","journal-title":"Br J Dermatol"},{"key":"1136_CR24","doi-asserted-by":"publisher","first-page":"204062231984375","DOI":"10.1177\/2040622319843756","volume":"10","author":"TY Ger","year":"2019","unstructured":"Ger TY, Huang YH, Hui RC, Tsai TF, Chiu HY. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019;10:2040622319843756.","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"1136_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, et\u00a0al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891\u2013904.","journal-title":"Am J Clin Dermatol"},{"key":"1136_CR26","doi-asserted-by":"publisher","first-page":"1185523","DOI":"10.3389\/fmed.2023.1185523","volume":"10","author":"S Piaserico","year":"2023","unstructured":"Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirisap N, et\u00a0al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med (Lausanne). 2023;10:1185523.","journal-title":"Front Med (Lausanne)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01136-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01136-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01136-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T14:03:11Z","timestamp":1714140191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01136-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01136-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April Armstrong has received grants or contracts from, and served as a consultant, speaker and\/or investigator for: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, UCB, Janssen, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Sun, Sanofi, and Regeneron; has participated on data safety monitoring or advisory boards for: Boehringer Ingelheim and Parexel; and has been elected to the Board of Directors for the American Academy of Dermatology. Alvaro Gonz\u00e1lez-Cantero has served as a consultant and speaker for: AbbVie, Almirall, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, L\u2019Oreal, MSD, Novartis, and UCB Pharma; and has received grants or contracts from: Almirall, Celgene, and LEO Pharma. Saakshi Khattri has received grants or contracts from, and\/or served as a consultant and\/or speaker for: AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB Pharma. Guilherme Muzy has received honoraria and\/or consulting fees from: AbbVie, Eli Lilly and Company, Sanofi, Novartis, Janssen, and Pfizer; has been a speaker for: AbbVie, Eli Lilly, Sanofi, Novartis, Janssen and Pfizer; and has participated on data safety monitoring or advisory boards for: Abbvie, Eli Lilly, Sanofi, Janssen, and Pfizer. William N. Malatestinic, Anastasia Lampropoulou, and Sophia Kyoungah See are employees and shareholders of Eli Lilly and Company. Meghan Feely is associate staff at Mount Sinai Hospital, Mount Sinai West, and Mount Sinai Morningside; a current employee and shareholder of Eli Lilly and Company; and has received consulting, travel, or speaker fees from: American Academy of Dermatology, Aerolase, Castle Biosciences, CeraVe\u2014L'Or\u00e9al, DREAM USA, Galderma Aesthetics, Glow Recipe, La Roche-Posay\u2014L'Or\u00e9al, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical. Can Mert is a contractor of HaaPACs GmbH and conducted statistical analysis for this project on behalf of Eli Lilly and Company. Andrew Blauvelt has served as a speaker (received honoraria) for: Eli Lilly and Company, Pfizer, and UCB Pharma; served as a scientific adviser (received honoraria) for: AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, ASLAN Pharmaceuticals, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO pharma, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for: AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All study protocols, amendments, and consent documentation were approved by the necessary central or local institutional review boards (IRB) and\/or ethics committees. All patients were required to give written informed consent prior to participation in UNCOVER-2, UNCOVER-3, IXORA-R, IXORA-S, or PSoHO. Each study was conducted in compliance with local laws and regulations and according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Helsinki Declaration of 1964, and its later amendments. We confirm that the necessary central or local IRB and\/or ethics committee approvals have been obtained for each study. Approvals can be provided on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}